ENANTA PHARMACEUTICALS ($ENTA) posted quarterly earnings results for Q2 2026 on Monday, May 11th. The company reported earnings of -$0.45 per share, beating estimates of -$0.50 by $0.05. The company also reported revenue of $17,160,000, missing estimates of $17,433,840 by $-273,840.
You can see Quiver Quantitative's $ENTA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ENANTA PHARMACEUTICALS Insider Trading Activity
ENANTA PHARMACEUTICALS insiders have traded $ENTA stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ENTA stock by insiders over the last 6 months:
- JAY R. LULY (President and CEO) sold 4,743 shares for an estimated $67,492
- YAT SUN OR (Chief Scientific Officer) sold 2,390 shares for an estimated $34,009
- TARA LYNN KIEFFER (Chief Product Strategy Officer) sold 2,106 shares for an estimated $29,968
- BRENDAN LUU (Chief Business Officer) sold 1,394 shares for an estimated $19,836
- HARRY R. III TROUT (See Remarks) has made 0 purchases and 2 sales selling 922 shares for an estimated $13,017.
- SCOTT T. ROTTINGHAUS (Chief Medical Officer) sold 798 shares for an estimated $11,355
- KATHLEEN S. CAPPS (See Remarks) has made 0 purchases and 2 sales selling 530 shares for an estimated $7,486.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ENANTA PHARMACEUTICALS Hedge Fund Activity
We have seen 80 institutional investors add shares of ENANTA PHARMACEUTICALS stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 1,956,867 shares (+inf%) to their portfolio in Q4 2025, for an estimated $30,859,792
- JANUS HENDERSON GROUP PLC added 1,782,745 shares (+91.6%) to their portfolio in Q4 2025, for an estimated $28,113,888
- BLACKROCK, INC. added 1,243,302 shares (+67.8%) to their portfolio in Q4 2025, for an estimated $19,606,872
- COMMODORE CAPITAL LP removed 800,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $12,616,000
- KRENSAVAGE ASSET MANAGEMENT, LLC added 651,946 shares (+30.8%) to their portfolio in Q4 2025, for an estimated $10,281,188
- FARALLON CAPITAL MANAGEMENT LLC added 650,000 shares (+30.6%) to their portfolio in Q4 2025, for an estimated $10,250,500
- VANGUARD GROUP INC added 362,965 shares (+18.7%) to their portfolio in Q4 2025, for an estimated $5,723,958
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ENANTA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ENTA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- JP Morgan issued a "Overweight" rating on 11/14/2025
To track analyst ratings and price targets for ENANTA PHARMACEUTICALS, check out Quiver Quantitative's $ENTA forecast page.
ENANTA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ENTA recently. We have seen 2 analysts offer price targets for $ENTA in the last 6 months, with a median target of $18.5.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $20.0 on 02/10/2026
- Anupam Rama from JP Morgan set a target price of $17.0 on 11/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
